$20.60
3.38% yesterday
Nasdaq, Jun 27, 10:11 pm CET
ISIN
US86627R1023
Symbol
SMMT
Sector
Industry

Summit Therapeutics PLC Sponsored ADR Stock price

$20.60
-5.04 19.66% 1M
+2.39 13.12% 6M
+2.76 15.44% YTD
+12.73 161.75% 1Y
+19.58 1,919.61% 3Y
+17.56 577.63% 5Y
+9.95 93.43% 10Y
+10.41 102.16% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.72 3.38%
ISIN
US86627R1023
Symbol
SMMT
Sector
Industry

Key metrics

Basic
Market capitalization
$15.3b
Enterprise Value
$14.9b
Net debt
$-361.3m
Cash
$361.3m
Shares outstanding
741.6m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
44.37
Financial Health
Equity Ratio
89.25%
Return on Equity
-56.93%
ROCE
-
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-315.7m
EBIT
-
Net Income
- | $-303.8m
Free Cash Flow
$-173.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -49.71%
EBIT
-
Net Income
- | -37.29%
Free Cash Flow
-85.08%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
FCF per Share
$-0.23
Short interest
26.17%
Employees
159.00
Rev per Employee
$0.00
Show more

Is Summit Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy
94%
Hold
6%

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
61% 61%
-
- Research and Development Expense 120 120
79% 79%
-
-169 -169
72% 72%
-
- Depreciation and Amortization 0.09 0.09
55% 55%
-
EBIT (Operating Income) EBIT -169 -169
72% 72%
-
Net Profit -178 -178
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Summit Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Summit Therapeutics PLC Sponsored ADR Stock News

Neutral
Schaeffers Research
16 days ago
With the way negative stock market sentiment  has piled up recently, short squeezes have generated some massive returns.
Negative
The Motley Fool
16 days ago
An analyst's downbeat new take on Summit Therapeutics (SMMT -11.05%) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors absorbed the negative take.
Neutral
Business Wire
21 days ago
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...
More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Robert Zanganeh
Employees 159
Founded 2003
Website www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today